trending Market Intelligence /marketintelligence/en/news-insights/trending/pRZft0iv5Jw-hZ12Suqbdg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Teva's prophylaxis generic gets sole EMA recommendation in October

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Teva's prophylaxis generic gets sole EMA recommendation in October

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of one generic medicine in October: Teva Pharmaceutical Industries Ltd.'s Tacforius, intended for prophylaxis and treatment of transplant rejection.

Separately, the EU panel recommended Roche Holding AG's Alecensa as a first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. The drug was previously recommended as monotherapy for patients that had already been treated with Pfizer Inc.'s Xalkori, or crizotinib.

Santhera Pharmaceuticals Holding AG requested a reexamination of the CHMP's negative opinion for Raxone, or idebenone, intended to treat Duchenne muscular dystrophy, a rare genetic condition characterized by progressive muscle weakness and degeneration. The EMA panel will re-examine the opinion and issue a final recommendation.

The CHMP did not adopt a negative opinion in its October meeting. Also, no company withdrew its application during the month.